HIV-1 induces activation of complement through the classical and lectin pathways. However, the virus incorporates several membrane-bound or soluble regulators of complement activation (RCA) that inactivate complement. HIV-1 can also use the complement receptors (CRs) for complement-mediated antibody-dependent enhancement of infection (C´-ADE). We hypothesize that hypofunctional polymorphisms in RCA or CRs may protect from HIV-1 infection. For this purpose, 139 SNPs located in 19 RCA and CRs genes were genotyped in a population of 201 Spanish HIV-1-exposed seronegative individuals (HESN) and 250 HIV-1-infected patients. Two SNPs were associated with infection susceptibility, rs1567190 in CR2 (odds ratio (OR) = 2.27, P = 1 × 10 − 4 ) and rs2842704 in C4BPA (OR = 2.11, P = 2 × 10 − 4 ). To replicate this finding, we analyzed a cohort of Italian, sexually HESN individuals. Although not significant (P = 0.25, OR = 1.57), similar genotypic proportions were obtained for the CR2 marker rs1567190. The results of the two association analyses were combined through a random effect meta-analysis, with a significant P-value of 2.6x10 − 5 (OR = 2.07). Furthermore, we found that the protective CR2 genotype is correlated with lower levels CR2 mRNA as well as differences in the ratio of the long and short CR2 isoforms.
INTRODUCTION
HIV-1 is able to activate the classical pathway of complement in the absence of antibodies. Such activation depends on the direct binding of C1q envelope protein 1 and the attachment of C3b on the viral membrane. This fact is enhanced in the presence of specific anti-HIV-1 antibodies. 2 In addition, HIV-1 interacts with mannose binding lectin through direct binding to gp120, triggering the activation of the complement lectin pathway. 3 However, the virus appears to be resistant to complement. 4, 5 The biological model to explain this fact is based on the active viral exploitation of the regulators of complement activation (RCA) protein family. The exploitation of RCA proteins by several families of viruses is a clear example of adaptive convergence. 6 In the case of HIV-1, the absorption of membrane-bound RCA proteins in virions has been demonstrated. 4, 7, 8 These proteins enhance virus resistance to complement-mediated lysis. 4, 9, 10 This incorporation contributes to the survival of HIV-1 in blood or other tissues as both virions and infected cells are resistant to neutralizing antibodies. 10 Other soluble proteins such as Complement Factor H (CFH) interacts with viral envelope. 11 Depletion of CFH in human serum increased destruction of cells infected by HIV-1 and free virus in vitro. 11, 12 Similarly, viruses produced in cells defective for any of the RCA proteins are extremely sensitive to killing by serum in the presence or absence of neutralizing antibodies. Interestingly, Streptococcus spp. has developed a similar strategy of resistance to serum by addition of CFH to its surface by the M protein. 13 Both complement and the RCA genes are extremely polymorphic, and in some cases, a functional effect of the polymorphisms has been found. 14 Complement-coated virions are concentrated in several tissues; especially the lymphatic system and can interact with complement receptors (CRs) that bind C3 fragments. Although viral inactivation through opsonization and lysis was observed, 15 CRs expression in T/B lymphocytes or erythrocytes can also boost viral infectivity in a process known as complement-mediated antibodydependent enhancement of infection (C´-ADE). 16 The CRs implicated in C´-ADE include CR1, CR2 and CR3. Both cis and trans C´-ADE were observed on cell lines as well as on primary cells and with primary isolates of HIV-1. 17 Regarding above interactions of HIV-1 with RCA and CRs, we hypothesized that individuals carrying polymorphisms that reduce the functional capacity of the CRs or RCA proteins or their site of interaction with gp120/gp41 could display a natural resistance to HIV-1 infection mediated by an increased probability of virolysis mediated by full complement activation or lower complementmediated enhancement of infection. To address this hypothesis, we have performed a genetic association analysis as well as a phenotypic characterization of RCA and CRs in two independent cohorts of HIV-1-exposed seronegative (HESN) and HIV-1-positive individuals.
RESULTS

Genotyping statistics
Four SNPs did not pass the genotyping quality controls of Illumina Veracode Golden Gate protocol rs7084554 (MBL2), rs12406509 (CFHR4), rs7046 (CD59) and rs9837104. Additionally, we found significant deviation from Hardy-Weinberg equilibrium (P = 1.3x10 − 5 ) in the marker rs9331949 (CLU). Mean genotyping call rate for the remaining SNPs was 99.6%.
Single SNP association analyses
We selected 143 polymorphic markers (Table 1) within RCA and CRs genes for susceptibility to HIV-1 association in the injection drug use (IDU)-Spain cohort. Two intronic SNPs positioned in the same region of the chromosome 1 (Figure 1 ) showed experimentwide significant allelic or genotypic association with resistance to HIV-1 infection. The G allele of rs2842704 in C4BPA was associated with decreased risk of infection under dominant model (P = 2.1 × 10 − 4 ; odds ratio (OR) = 0.47 (0.31-0.70)). Subjects carrying GG+AG genotypes were significantly over-represented in HESN group (43%) compared with HIV-1-infected one (26%) ( Tables 2A and 2B ). Regarding CR2 gene, rs1567190-T allele was associated with increased risk of HIV infection under a dominant model (P = 1.9 × 10 − 4 ; OR = 2.27 (1.46-3.51)) (Tables 2A and 2B ). Subjects carrying TT+CT genotypes were significantly overrepresented in the HIV-1-positive group (81%) compared with HESN (65.5%) (Tables 2A and 2B ). Three other SNPs showed a trend to association with HIV-1 infection protection but did not reach statistical significance after correction for multiple testing; rs419137 in CFH (P = 6x10 − 3 ), rs831618 in CD59 (P = 7 × 10 − 3 ) and rs6690037 in C4BPB (P = 8 × 10 − 3 ) ( Supplementary Table 1 ).
Additionally, to replicate our previous findings, rs2842704 in C4BPA and rs1567190 in CR2 were genotyped in a second population (Sexual-Italy) exposed to the virus through sexual route. Both genetic markers were consistent with Hardy-Weinberg proportions. Genotype distribution of rs2842704 marker differs to that observed in the IDU-Spain sample therefore not supporting the observed association for this SNP in the IDU-Spain cohort (Tables 2A and 2B) .
Similarly to what was observed in the Sexual-Italy sample, CR2 rs1567190 TT+TC genotype was over-represented in HIV-1 (77.5%) compared with HESN (68.5%), although it did not reach statistical significance (P = 0.25; OR = 1.57 (0.7-3.4)) Tables 2A and 2B). The results of the two association analyses were combined through a random effect meta-analysis, with a significant P-value of 2.6 × 10 − 5 (Tables 2A and 2B ). These observations suggest that the rs1567190-T allele confers risk to HIV-1 infection with a dominant effect, independently of the infection route.
Haplotype association analysis in Spanish intravenous drug users A haplotype-based association test was performed by multimarker regression analysis using PLINK and Haploview software. Haplotype frequencies were estimated and compared between the two groups of the IDU-Spain cohort. This analysis identified three haplotypes associated with HIV-1 resistance with a significant multiple-testing P-value o 5 × 10 − 3 . Haplotypes from CFH, C4BPA and CR2 genes included SNPs previously identified as associated in the univariate analysis (Table 3 ). Using PLINK software, we calculated the chromosome phases for HESN and HIV groups and performed haplotype copy number calculation in HIV-1-positive and HESN individuals. The presence of two copies of the CGGGG haplotype encompassing the promoter, and the first 12 exons of CR2 (rs1567190, rs1507764, rs1048971, rs17615 and rs4317805) showed the strongest association with protection under a recessive model (P = 4.2 × 10 − 5 ) ( Table 3 ). The other two haplotypes associated with innate resistance to HIV-1 infection followed a dominant model and included the presence of one or two copies of the haplotype GCT (rs2842704, rs4425986 and rs9943077) located in the fourth intron of C4BPA (P = 1.1 × 10 − 3 ) (Table 3) , as well as the haplotype AAACTGCG (rs2019727, rs6695321, rs10737680, rs419137, rs395544, rs2284664, rs11582939, rs16840658) that spans from the intron 9 of CFH to the 5′ end of CFHR1 gene ( Table 3) .
Sequencing of C4BPA, CD55, CR2 and CR1 chromosome region To identify new functional SNPs linked with the protective genotypes in CR2 and C4BPA in the candidate region and perform a sequence haplotyping, a mean of 900 000 bp were sequenced confidently with a 30 × mean coverage. The target region included C4BPB, C4BPA, CD55, CR2, CR1 and CR1L genes (207, 224, 740, 299 ; GRCh37/hg19). Five pools of HIV-1positive homozygous for the risk (T) allele of the SNP rs1567190 and three pools of HESN patients homozygous for the protective (C) allele of the SNP rs1567190 were sequenced. The main statistics for pool sequencing can be found in Supplementary  Table 2 . We observed a perfect match between the two genotyping systems Veracode Golden Gate and Next Generation Sequencing. The individuals homozygous for the C allele of rs1567190 are also homozygous for 52 polymorphisms spanning 45 Kb of the CR2 gene ( Figure 2 ). In particular, these individuals are homozygous for the coding SNPs rs1048971, rs17615, rs4308977 and rs17616 (G-G-T-G). On the contrary, individuals homozygous for the risk allele of rs1567190 displayed a higher level of heterozygosity along the CR2 gene with only 11 homozygous polymorphisms and only 1 of them (rs17258982) located in the CR2 coding region ( Figure 2 ). No new coding SNPs were detected in the region.
CR2 and C4BPA phenotyping Next, we validated whether the observed effect could be associated with differential expression of CR2 mRNA in peripheral blood mononuclear cells (PBMCs) from healthy donors. Nine rs1567190-CC and nine rs1567190-TT homozygous samples were examined by Taqman real-time quantitative PCR. The relative amount of the CR2 expression of different genetic backgrounds was normalized to CD19 (a specific B-lymphocyte marker). We found a lower level of expression of the protective genotype CC (mean = 0.89 ± 0.34) compared with the risk genotype TT (mean = 1.36 ± 0.38; P = 0.029, student T-test, Figure 3 ). These data suggest that the global level of CR2 expression is increased in B-lymphocytes from rs1567190 TT carriers. These data represent the mean of two independent experiments performed in triplicate. The levels of the short and long CR2 mRNA splicing isoforms were also quantified by real-time PCR in both genetic backgrounds. The CD19-normalized short CR2 isoform expression was significantly reduced in PBMCs from homozygous CC individuals compared with TT (mean = 0.37 ± 0.04 vs 1.25 ± 0.89; P = 0.02, student T-test, Figure 3 ). Finally, we have found that the expression of long CR2 isoform in rs1567190-CC carriers is higher compared with the other genotype (mean = 5.0 ± 3 vs 0.21 ± 0.23; P = 0.0026, student T-test, Figure 3 ).
DISCUSSION
In this hypothesis-driven, low-scale, candidate gene association study, we have genotyped 139 SNPs in 19 genes related to complement regulatory proteins or CRs. Our discovery population is highly uniform: all are male, white Caucasians of Spanish ancestry, Hepatitis C virus-positive and intravenous drug users; including 201 HESN and 250 HIV-1-positive. We found two SNPs that are significantly associated after Bonferroni's correction with resistance to HIV-1 infection; rs1567190 located in CR2 and rs2842704 in C4BPA. In the replication cohorts from Italy, we did not detect significant association probably because of the small size and lack of power. However, similar proportions in rs1567190 CR2 genotypes were observed in this population compared with the Spanish one; HESN subjects are more likely to be homozygous for the C allele than HIV-1-infected patients. Consequently, 3UTR  rs12272807 11 33698323  intron  rs704700  11 33700109  intron  rs831627  11 33702622  intron  rs831626  11 33702925  intron  rs17760694 11 33713667  intron  rs2273121  11 33714345  intron  rs11032362 11 33715667  5UTR  rs28362934 11 57120118 SERPING1  5UTR  rs11603020 11 57130907  intron  rs2508443  11 57134567  intron  rs2511988  11 57135745  intron  rs2072449  12  8101903  C3AR1  3UTR  rs11567785 12  8109919  3UTR  rs11567782 12  8111186  5UTR  rs17728664 12  8115730  5UTR  rs7253663  19 52500667  C5AR1  5UTR  rs4427917  19 52507554  intron  rs4577202 19 52507761 intron Abbreviations: NS, non-synonymous; S, synonymous; SNP, single nucleotide polymorphism; UTR, untranslated region.
Complement genetics and HIV-1 infection although statistical analysis was significant for the Spanish cohort only, the meta-analysis that we performed revealed no heterogeneity in the effect of rs1567190 among the two populations and yielded a robust significant association. This study has several limitations; first, the list of genes related to complement system is not exhaustive. Second, our phenotypic analysis is limited to mRNA expression, and third, the replication cohort from Italy is significantly smaller than the Spanish one.
The CR2 gene encodes a membrane protein also known as CD21, which functions as a receptor for C3d/iC3b among other molecules. [18] [19] [20] CR2 gene contains 18 exons and there exist two main isoforms that result from alternative splicing of exon 11: CR2-L and CR2-S. The first form is expressed mainly in follicular dendritic cells and contains 16 short consensus repeats; the second isoform contains 15 short consensus repeats and is expressed mainly in B-lymphocytes. The specific functions of each isoform as well as its binding capacity to the natural ligands are unknown.
CR2 function can be subverted by some viruses that use antibodies and/or complement for a highly efficient entry into target cells in a process known as C´-ADE of viral infection. Although C´-ADE is not a well-established factor in acquisition of lentiviruses infections in either humans or animals, two types of ADE have been suggested in the context of HIV-1. The first type of ADE is dependent on the interaction between antibody and FcγRIIIa. Polymorphisms in this gene were associated with outcomes in preventive HIV-1 vaccination trial. 21 Second, complement alone can boost infection of dendritic cells as well as monocytes/macrophages and antibodies can augment this process by a more efficient recruitment of complement on the viral surface. This mechanism is dependent on the CR2/CR1 expression in the target cells 17, 22 and probably is mediated by an increased adhesion of the virus-antibody-complement (C3d) complexes through binding with CR2 on the target surface. 23, 24 The protective SNP identified in this study belongs to an extended haplotype that displays strong linkage disequilibrium and includes other 52 genetic polymorphisms that span 45 Kb from the promoter to 3′ downstream region. The protective CR2 haplotype displays lower levels of total CR2 mRNA as well as reduced short isoform expression. In view of the data about the role of CR2 in C´-ADE, we hypothesize that the ratio of short/long CR2 isoform expression and/or the global CR2 level may contribute to the likelihood of HIV-1 acquisition through the parenteral as well as sexual routes. ADE is an important factor affecting other viruses as Dengue, Ross River or Ebola; 16 we conjecture that the CR2 haplotypes could have also an influence in the susceptibility to these viruses. Although the main SNP identified in this study has not been previously related with any pathology, the protective haplotype has been associated with susceptibility to systemic lupus erythematosus. 25, 26 C4BPA gene encodes a plasma protein that forms an oligomer complex with C4BPB, producing three isoforms. C4BP is a plasmid regulator of the classical and alternative complement pathways. Flaviviruses actively recruit C4BP through the NS1 protein, reducing the functional capacity of C4 and complement activation. 27 Bacterial infections such as Streptococcus, 28 Yersinia, 29 Lepstospira 30 or Neisseria 31 among others have also developed active protein systems to capture C4BP in the surface to escape complement-mediated lysis. The observed association of C4PBA haplotypes with HIV-1 resistance in HESN at risk through the parenteral route suggests that this gene could be a candidate for further functional phenotypic characterization.
Several observations may underlie the absence of association of C4BPA marker in the Italian cohort. First, this cohort is mainly constituted by women 32 and the Spanish one is exclusively constituted by males. There are significant gender differences in the innate and adaptive immune responses, the pathogenesis of infectious diseases, response to vaccines and the prevalence of autoimmune diseases. 33, 34 In the case of C4BP, the synthesis appears to be influenced by sex hormones. [35] [36] [37] CFH regulates the function of the alternative complement pathway in fluid phase and on cellular surfaces. SNPs in the CFH region that appears to be related with HIV-1 resistance at the haplotypic level were previously associated with several Abbreviations: CI, confidence interval; HESN, HIV-1-exposed seronegative; ND, Not determined (because of opposite effects in the two cohorts); OR, odds ratio. Underlined: % of allele or genotypes with significant differences between HESN and HIV+ cohorts. Abbreviations: CI, confidence interval; HESN, HIV-1-exposed seronegative; ND, Not determined (because of opposite effects in the two cohorts); OR, odds ratio. Underlined: % of allele or genotypes with significant differences between HESN and HIV+ cohorts.
Complement genetics and HIV-1 infection autoimmune diseases; 14 as well as susceptibility to meningitis 38 and Dengue. 39 High levels of CFH in human serum can protect cells infected by HIV-1 and free virus in vitro. 12 We hypothesize that the protective haplotype of CFH may be related to lower levels of CFH expression by the liver or altered splicing efficacy. The inhibition of membrane-bound RCA has been proposed as new therapeutic target against HIV-1. In the case of CD59, 40 the presence of specific inhibitors of this protein renders HIV-1 virions highly sensitive to complement-mediated lysis activated by antibodies. The results presented here, if confirmed, could lead to developm a similar approach to combat the viral infection by the means of development of new antagonists of CR2, C4BPA or CFH.
MATERIALS AND METHODS
Patients and controls
We recruited 451 Hepatitis C virus-seropositive white males exposed to HIV-1 by IDU (IDU-Spain) that had shared needles for 43 months. Of the subjects, 250 were HIV-1-seropositive and 201 HIV-1-seronegative (HESN). This cohort was enrolled in prospective studies in Spain and their epidemiological and clinical characteristics were described in previous studies. Additionally, a second population exposed to HIV-1 infection by sexual route, all of whom are part of a serodiscordant heterosexual couple that had unprotected sexual events, was analyzed as replication population; both HIV-1-infected (62 subjects) and HESN (80 subjects). This cohort was enrolled in prospective studies in Italy (Sexual-Italy). The main characteristics of this population were previously described. 32 
Ethical aspects
The study was designed and performed according to the Helsinki declaration and was approved by the Human Subject Institutional Review Boards to the Ethics Committee of the participating hospitals. The University of Jaen's Bioethics Institutional Review Board approved the transfer and use of materials for this research. All patients and donors provided written informed consent to participate in this study.
Polymorphisms selection and genotyping
SNPs from complement regulatory genes (Table 1) 
Biostatistics and bioinformatics
Hardy-Weinberg equilibrium and pairwise linkage disequilibrium (D′) were calculated using Haploview V4.1 software. Block structure was considered for marker pairs showing D′40.8, following the solid-spine block definition implemented in Haploview. Single marker and haplotype frequencies were estimated and compared using PLINK software. Complementary analysis was performed by use of SPSS software (version 14.0, IBM Corporation, Armonk, NY, USA). Single-marker association P-values were corrected for multiple testing following the SNP spectral decomposition approach, 41 experiment-wide significance threshold required to keep type I error rate at 5% was 5 × 10 − 4 . Haplotype association tests were adjusted using Bonferroni's correction for multiple testing by dividing the significance level (0.05) by the number of major haplotypes (that is, 45%), a P-value o5 × 10 − 3 was considered statistically significant.
CR2 mRNA quantification
PBMCs from healthy blood donors were purified by centrifugation in Ficoll gradient, DNA was extracted as previously described and genotyped for the SNPs rs1567190 of CR2 with Taqman probes. Nine individuals harboring CC genotype and nine with TT genotype for CR2 were randomly selected for gene expression analyses. Then, from each sample, total RNA from 5 × 10 6 PBMCs was isolated using Tripure reagent (Roche), quantified by spectrophotometry and dissolved at 1 μg μl − 1 . Reverse transcription of RNA was performed using the Superscript III (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions. All the RNA samples were also subjected to control reactions without reverse transcriptase to check for contamination. The normalized CR2 expression was determined in a multiplexed, one tube PCR reaction on a MX3005P thermocycler (Stratagene, La Jolla, CA, USA). CR2 transcript levels were quantified using the Applied Biosystems Assay Hs00153398_m1 (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. A CD19 assay was used as endogenous control (Hs01047410_g1, Applied Biosystems). Each donor cDNA was amplified in triplicate wells and repeated in two independent days. At the same time, negative control Complement genetics and HIV-1 infection experiments were done with reverse transcriptase-negative cDNAs. The relative expression of CR2 mRNAs compared with endogenous CD19 (CR2) were calculated with MX-pro-V4.0 software (Stratagene). The Comparative quantitation of short and long isoform of CR2 transcripts was done as previously described. 25 
